Ultragenyx Pharmaceutical (RARE) News Today $39.42 -0.19 (-0.48%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$39.40 -0.02 (-0.05%) As of 07/8/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RARE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by KBC Group NVJuly 8 at 3:37 AM | marketbeat.comWCM Investment Management LLC Has $7.65 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)July 3, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 3, 2025 | americanbankingnews.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by AnalystsJuly 3, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 6.3% - Should You Buy?July 2, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Shares Cross Below 50 Day Moving Average - What's Next?July 1, 2025 | marketbeat.comUltragenyx stock rises after FDA grants breakthrough therapy status for Angelman syndrome drugJune 27, 2025 | au.investing.comUltragenyx Gets FDA Designation to Expedite GTX-102 Drug DevelopmentJune 27, 2025 | marketwatch.comUltragenyx Pharmaceutical Inc. Receives FDA Breakthrough Therapy Designation for GTX-102 to Treat Angelman SyndromeJune 27, 2025 | quiverquant.comQUltragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman SyndromeJune 27, 2025 | globenewswire.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) D. Sanders Sells 2,405 SharesJune 24, 2025 | insidertrades.comInsider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Sells 2,405 Shares of StockJune 23, 2025 | marketbeat.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 20, 2025 | globenewswire.comGuggenheim Reaffirms Buy Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)June 20, 2025 | marketbeat.comGAMMA Investing LLC Acquires 26,625 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 17, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Assenagon Asset Management S.A.June 15, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Sells 14,701 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 15, 2025 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 3.5% - What's Next?June 12, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by SG Americas Securities LLCJune 12, 2025 | marketbeat.comWedge Capital Management L L P NC Buys Shares of 35,695 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 11, 2025 | marketbeat.comResearch Analysts Offer Predictions for RARE FY2026 EarningsJune 10, 2025 | marketbeat.comChina's rare earth exports climb 23% in May ahead of trade talks with the U.S.June 9, 2025 | msn.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 8, 2025 | marketbeat.comUltragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare ConferenceJune 3, 2025 | globenewswire.comMackenzie Financial Corp Acquires 11,825 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 2, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Takes Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 1, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)June 1, 2025 | marketbeat.comEquities Analysts Offer Predictions for RARE FY2025 EarningsMay 31, 2025 | marketbeat.comWilliam Blair Begins Coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE)May 29, 2025 | marketbeat.comWilliam Blair Initiates Coverage of Ultragenyx Pharmaceutical (RARE) with Outperform RecommendationMay 29, 2025 | msn.comSquarepoint Ops LLC Purchases Shares of 87,989 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 28, 2025 | marketbeat.comUltragenyx’s SWOT analysis: rare disease biotech stock poised for growthMay 26, 2025 | investing.comTwinbeech Capital LP Raises Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 24, 2025 | marketbeat.comTwo Sigma Investments LP Has $25.87 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 24, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Frazier Life Sciences Management L.P.May 23, 2025 | marketbeat.comBank of America Corp DE Has $16.34 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 23, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 74,300 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 22, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) is Vestal Point Capital LP's 5th Largest PositionMay 21, 2025 | marketbeat.comMillennium Management LLC Sells 13,453 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 21, 2025 | marketbeat.comSherbrooke Park Advisers LLC Acquires Shares of 10,387 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 20, 2025 | marketbeat.comMan Group plc Trims Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 20, 2025 | marketbeat.comSphera Funds Management LTD. Has $9.63 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 18, 2025 | marketbeat.comPoint72 Asset Management L.P. Grows Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 18, 2025 | marketbeat.comPoint72 Hong Kong Ltd Grows Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 18, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comParkman Healthcare Partners LLC Has $4.21 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 16, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 16, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $12.04 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)May 16, 2025 | marketbeat.comUltragenyx Pharmaceutical Inc.: Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact ReportMay 15, 2025 | finanznachrichten.de Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address RARE Media Mentions By Week RARE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RARE News Sentiment▼1.030.57▲Average Medical News Sentiment RARE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RARE Articles This Week▼58▲RARE Articles Average Week Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Genmab A/S News Dr. Reddy's Laboratories News Moderna News Regencell Bioscience News Viatris News Ascendis Pharma A/S News QIAGEN News Blueprint Medicines News BridgeBio Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RARE) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
